In this episode of #HealthTechDeals, Jess is enjoying Cinqo de Mayo in an Addams Family-themed hotel where she is playing “the mummy” introducing health tech companies coming back from the dead. There’s gossip about Amazon’s pharmacy operation over supplying insulin, and there’s deals for Levels ($38m) in CGM analysis, Waltz Health ($35m) in pharmacy search, Safety Wing ($25m) for health insurance for nomads & Implicity ($23m) doing cardiac implantable monitoring in France.
#HealthTechDeals Episode 26: Hello Heart, Concert Health, Vivian Health, Curebase, Mendel.ai & Blue Spark
It’s the May the 4th be with you day! In Episode 26 of #HealthTechDeals, Jessica is huddling in Boston after the American Telehealth Association conference, and has Star Wars-related trivia. There’s gossip there, there’s more gossip about Cerebral & its ADHD med strategy. Meanwhile a lot of copy cats in deals today with Hello Heart ($70m) for hypertension, Concert Health ($40m) for mental health, Vivian Health ($60m) for nurse staffing, Curebase ($40m) for DCTs, Mendel.ai ($40m) for NLP & Blue Spark ($40m) for RPM — all joining very crowded markets.
#HealthTechDeals Episode 24: Carbon Health, Clipboard Health, Source Health, and Diligent Robotics
Happy 4/20 everybody! Smoking weed live on Health Tech Deals is not to be encouraged, but Jess and I embrace the natural high of discussing the multitude of million-dollar deals in health technology: Carbon Health enters diabetes care; Clipboard Health raises $50 and $30 million; Source Health raises $3 million; and Diligent Robots raises $30 million.
-Matthew Holt
#HealthTechDeals Episode 23; Real, Iris Telehealth, 9am Health, Eko & Duos
In this episode of Health Tech Deals, Jess thinks the music has stopped as Rock Health reports Q1’s funding total being below Q4 2022! No $100m rounds today! But still $37m for Real; $40m for Iris Telehealth; only $16m for 9am Health but lots of Livongo connections; $30m for Eko and $15m for Papa-lookalike Duos
-Matthew Holt
#HealthTechDeals Episode 22: Viz.ai, PocketHealth, Eleanor Health, Recora, and Vytalize Health
3 big deals for this episode of Health Tech Deals! Tiger, General Catalyst, and e-Patient Dave are back! Check out this episode to hear my thoughts on them and on new deals in health tech: Viz.ai raises $100 million, PocketHealth raises $16 million, Eleanor Health raises $50 million, Recora raises $20 million, and Vytalize Health raises $50 million.
-Matthew Holt
#HealthTechDeals Episode 21: IntelyCare, Avi Medical, Eleos Health, Evernow & Vivosense
Well at least my hair is under control today. What’s not under control is the chatter about Olive from Erin Brodwin at Axios, even if I don’t get Jess’ joke about the internet of Health Care. Meanwhile deals in nursing recruitment for IntelyCare ($115m), Avi Medical (50M Euros), Eleos Health ($20m), Evernow ($20m) and $25m for Vivosense–note my total inability to say their investor’s name!–Matthew Holt
#HealthTechDeals Episode 20: Clarify Health, Season, Altoida, nirvanaHealth, and Pluto
What’s with my baseball hat? Find out in this episode! Apparently, someone thinks my hair is a bit out of control and needs some trimming. In this episode of Health Tech Deals, Jess and I review Clarify Health raising $150 million; Season raising $34 million; Altoida grabbing $20 million; nirvanaHealth getting $60 million; and Pluto Health raising $9 million–Matthew Holt
#HealthTechDeals Episode 18: Huma, Afterlife, Timedoc Health Avive, Antidote Health
Exciting things are a-happening in the Medicaid space! Two new female CEOs are being announced today in City Block Health and in Centene! In this episode of Health Tech Deals, Jess and I discuss new leadership changes in the health tech space, as well as new deals: Huma buys Astra Zeneca Digital; Afterlife raises $22 million; Timedoc Health raises $48.5 million; Avive raises $22 million; Antidote Health raises $22 million.
#HealthTechDeals Episode 17: Cricket Health, Embold Health, Canopy, Vira Health, and Woebot
We’ve reViVEd from ViVE and the HIMMSanity is over! Jess and I are back to discuss more multimillion-dollar deals: Fresenius/Interwell/Cricket Health is merging to 2.4 billion valuation; Embold Health gets $26 million; Canopy gets $13 million; Vira Health gets $12 million; and Woebot gets $9 million.
-Matthew Holt
Jess DaMassa:
While we revived from Vive and the HIMSS-sanity is over and all that’s left is boring old Matthew Holt and I to pick up the pieces. It can only be the March 22nd episode of Health Tech Deals.
Matthew Holt:
So Jess, I had massive HIMSS FOMO. First time hadn’t been in like 428 years and everyone else was there. And did you care? No?
Jess DaMassa:
I’m two hours away and I’m like, “Nope. Not for me. Not right now.”
Continue reading…#HealthTechDeals Episode 16: Doctolib, House Rx, SmithRx, Synapse Medicine, and Kintsugi
May the luck of the Irish be with the health tech sector and may everybody’s valuation go back to where it was for the St. Patrick’s Day episode of Health Tech Deals! In today’s episode, Jess asks me about Doctolib’s €500 million raise with a massive €5.8 billion valuation – this is a doctor booking service and more in Europe. We also cover specialty pharma company House Rx’s $25 million raise, bringing their total up to $30 million, SmithRx’s $27 million raise for its flat-fee PBM, Synapse Medicine’s $28 million raise doing medication management, and Kintsugi’s $20 million raise for its voice biomarker mental health tech. —Matthew Holt
TRANSCRIPT
Jessica DaMassa:
What’s that over there? Is that a little leprechaun sitting next to a pot of gold at the end of a rainbow? No, it’s just Matthew Holt. May the luck of the Irish be with the health tech sector and everybody’s valuation goes back to where it was in the summer of 2021. It can only be the March 17th ,St. Patty’s day, episode of Health Tech Deals.
Matthew Holt:
So, Jessica you’re from Chicago, right?
Jessica DaMassa:
I am.
Matthew Holt:
And they have the big St. Patrick’s Day Parade there and they dye the river green?
Jessica DaMassa:
They dye the river green. Nobody believes it but it’s true.
Matthew Holt:
So why don’t they dye it blue the rest of the year?
Continue reading…
